Omecamtiv Mecarbil (CK-1827452): Technical Guidance for Cardiac Research

What This Product Solves

Omecamtiv Mecarbil (CK-1827452) addresses a persistent challenge in preclinical models of systolic heart failure: selectively enhancing cardiac muscle contractility without increasing myocardial oxygen consumption or altering calcium handling. As a potent activator of the cardiac myosin S1 domain, it enables researchers to modulate actin-myosin interactions and contractile strength in isolated cardiomyocytes and in vivo heart failure models. Its selectivity profile—targeting only cardiac myosin and sparing other muscle types—makes it a precise tool for dissecting mechanisms of left ventricular systolic dysfunction and for probing myosin ATPase activation workflows.

Protocol Parameters

• in vitro cardiomyocyte contractility assay | 200 nM | adult rat cardiac myocytes | Demonstrated to significantly increase contractility at this concentration | product_spec (source)
• solubility in DMSO | ≥19.1 mg/mL | preparation of concentrated stock solutions | Ensures sufficient compound concentration for dilution into working solutions; DMSO preferred over water due to water insolubility | product_spec (source)
• storage temperature | -20°C (solid); below -20°C (DMSO stocks) | long-term compound and stock preservation | Maintains chemical integrity and prevents degradation; avoid repeated freeze-thaw cycles | product_spec (source)
• working solution solvent | DMSO or ethanol; avoid water | cell-based and biochemical assays | Compound is insoluble in water; DMSO and ethanol provide reliable solubilization for accurate dosing | workflow_recommendation
• EC50 for actin-myosin modulation | 2.3 μM | dose-response studies | Guides titration for functional studies targeting cardiac myosin S1 | product_spec (source)

Workflow Setup and QC Checklist

• Compound Handling: Use appropriate PPE and minimize exposure to ambient moisture. Weigh Omecamtiv Mecarbil quickly and dissolve immediately in DMSO or ethanol to achieve desired stock concentrations. Avoid prolonged handling at room temperature.
• Stock Solution Preparation: Prepare concentrated stocks (e.g., 10–20 mM) in DMSO, filter sterilize if required, and aliquot to minimize freeze-thaw cycles. Label aliquots with preparation date and concentration.
• Storage: Store both solid and solution forms at -20°C or below. Do not store working solutions for extended periods; discard if precipitation or discoloration occurs.
• Assay Setup: Dilute stock solutions into assay buffer immediately before use, ensuring final DMSO/ethanol concentration is compatible with cell or tissue model (typically ≤0.1–0.2%). Include vehicle controls in every experiment.
• Quality Control: Verify solubility visually and by absorbance, as appropriate. Validate compound activity in pilot assays using a titration series to confirm expected contractility effects or EC50 alignment.
• Documentation: Record lot numbers, storage conditions, and preparation protocols in laboratory notes for reproducibility.

Common Failure Modes and Fixes

• Precipitation in Aqueous Media: Omecamtiv Mecarbil is insoluble in water. If precipitation occurs upon dilution, increase DMSO content in the working solution (while staying within cell tolerance limits) or re-dissolve in ethanol if compatible with your assay. Always filter solutions before use if precipitation is suspected.
• Loss of Activity After Long-Term Storage: Decreased efficacy may result from repeated freeze-thaw cycles or prolonged storage of stock solutions. Always aliquot fresh stocks and avoid long-term storage of diluted solutions. Prepare working aliquots just prior to use and discard leftovers.
• Vehicle Toxicity Effects: High concentrations of DMSO or ethanol can confound results in sensitive cell systems. Ensure that vehicle controls match the highest solvent concentration used in any treatment group and adjust protocol to minimize solvent exposure.
• Batch-to-Batch Variability: Document all product details, including supplier and lot number (e.g., APExBIO, SKU A8349), to track and troubleshoot any inconsistencies.

Scope and Limitations

This compound is specifically designed for research on cardiac muscle contraction modulation, particularly in models of systolic heart failure and left ventricular systolic dysfunction. It is not suitable for studies involving skeletal or smooth muscle myosins, nor for applications requiring compound solubility in aqueous media. Omecamtiv Mecarbil’s use should be limited to protocols where precise control of solvent conditions and temperature is possible. The compound does not affect contraction or relaxation rates or calcium transients, so workflows dependent on these parameters should consider alternative agents. No support is provided for clinical or diagnostic use, nor for cross-tissue applications beyond the cardiac context established in the product dossier.

Conclusion

Omecamtiv Mecarbil (CK-1827452) offers a targeted approach for investigating cardiac myosin S1 domain activation and cardiac contractility enhancement in preclinical research. Careful attention to solubility, storage, and dosing is essential for reproducible results. For full technical specifications and ordering, consult the Omecamtiv Mecarbil (CK-1827452) product page from APExBIO.